First Crystal Structure of a Stress Hormone Receptor Reveals How It Works Inside Cell Membranes | Research

The takeaway

Scientists solved the first crystal structure of the transmembrane domain of a class B GPCR — the stress hormone receptor CRF1 — revealing how peptide hormone receptors work and opening new avenues for depression and anxiety drug design.

First-ever class B GPCR transmembrane structure
This Nature paper solved the first crystal structure of the membrane-spanning signal domain for the entire class B GPCR family — receptors targeted by drugs for diabetes, osteoporosis, depression, and more.

What the researchers found

The crystal structure of the human CRF1 receptor transmembrane domain was solved in complex with the small-molecule antagonist CP-376395. The structure revealed detailed atomic-level interactions between the receptor and the non-peptide ligand, which binds deep within the receptor's transmembrane helices.

This was the first transmembrane domain structure determined for any class B GPCR — a receptor family that was previously understood only from structures of its extracellular domain. The structure serves as a template for understanding the entire class B GPCR family, which includes receptors for many important peptide hormones (glucagon, GLP-1, PTH, calcitonin, and others).

Why it matters

Class B GPCRs are targets for treating depression, anxiety, diabetes, osteoporosis, and metabolic diseases — collectively affecting hundreds of millions of people. Before this structure, drug designers working on these receptors were essentially working blind in the membrane-spanning region. This structure revealed for the first time how small molecules interact with this entire receptor family at the atomic level, potentially accelerating the development of new drugs for stress-related and metabolic disorders.

How the study worked

The researchers used X-ray crystallography to determine the three-dimensional atomic structure of the transmembrane (signal-transducing) domain of the human corticotropin-releasing factor receptor type 1 (CRF1R). The receptor was crystallized in complex with CP-376395, a small-molecule antagonist that binds within the transmembrane region. The structure was expressed and purified from human HEK293 cells.

What this study cannot tell us

The crystal structure captures the receptor in a single, static conformation bound to an antagonist — it does not show the dynamic conformational changes that occur during receptor activation by peptide hormones. The transmembrane domain was crystallized without the extracellular domain, so the full picture of how peptide hormones bind and activate the complete receptor is incomplete. Crystal packing conditions may not perfectly reflect the receptor's natural membrane environment.

How to read the evidence

This is a high-impact structural biology study published in Nature, one of the world's most prestigious scientific journals. Crystal structures represent definitive experimental evidence for protein architecture. As a foundational structural study, it does not address therapeutic outcomes but provides essential infrastructure for drug design across the entire class B GPCR family.

When this study was published

Published in 2013, this was a pioneering structural study. Since then, numerous additional class B GPCR structures have been solved — including full-length structures and active-state conformations — building on the foundation this study established. The CRF1 receptor itself remains an active drug target.

The bigger picture

This was a landmark study in structural biology and drug discovery. Class B GPCRs are the receptors for many of medicine's most important peptide hormones — GLP-1 (diabetes/obesity drugs like semaglutide), PTH (osteoporosis drugs), calcitonin (bone metabolism), and glucagon (blood sugar regulation). Solving the CRF1 structure opened the door to understanding how all these receptors transmit signals across cell membranes and how drugs can be designed to modulate them. The study helped catalyze a wave of subsequent class B GPCR structures that has transformed peptide drug design.

Questions still open

What does the full-length CRF1 receptor look like with both the extracellular and transmembrane domains connected?
How does the receptor change shape when activated by its natural peptide hormone CRF?
Can this structural information accelerate the development of effective CRF1 antagonists for depression and anxiety treatment?

Common questions

What is a class B GPCR and why is its structure important?

Class B GPCRs are a family of receptors on cell surfaces that respond to peptide hormones — chemical messengers that control stress responses, blood sugar, bone health, and more. Knowing the exact 3D shape of these receptors at the atomic level allows scientists to design drugs that fit precisely into specific binding sites, like designing a key for a lock. Before this study, no one had seen the critical signal-transmitting portion of any class B receptor.

What is corticotropin-releasing factor and why target its receptor?

CRF is the body's primary stress-activating hormone — it triggers the fight-or-flight response and the release of cortisol. Overactive CRF signaling is linked to depression, anxiety, and stress-related disorders. Blocking the CRF1 receptor with drugs could potentially treat these conditions by dampening the stress response. This crystal structure shows exactly how blocking molecules fit into the receptor.

Read the original research

Structure of class B GPCR corticotropin-releasing factor receptor 1.

Nature, 499(7459), 438-43

View on PubMed ↗Publisher’s paper ↗

Citation

Hollenstein, Kaspar; Kean, James; Bortolato, Andrea; Cheng, Robert K Y; Doré, Andrew S; Jazayeri, Ali; Cooke, Robert M; Weir, Malcolm; Marshall, Fiona H. (2013). Structure of class B GPCR corticotropin-releasing factor receptor 1.. Nature, 499(7459), 438-43. https://doi.org/10.1038/nature12357